Role of genetic variations of chitinase 3-like 1 in bronchial asthmatic patients

  • Kazuyuki Abe
  • Yutaka Nakamura
  • Kohei Yamauchi
  • Makoto Maemondo
Open Access
Research
  • 366 Downloads
Part of the following topical collections:
  1. Respiratory Allergy

Abstract

Background

Single nucleotide polymorphisms (SNPs) in chitinase 3-like 1 (CHI3L1) are associated with bronchial severity and pulmonary function. CHI3L1 proteins are involved in both innate and adaptive immune responses; however, to date, the correlation of these SNPs and their age of onset of bronchial asthma has not been demonstrated.

Methods

To address the role of these genetic variations, 390 patients with well-controlled bronchial asthma and living in Japan were recruited, genotyped, and had a pulmonary function test performed on them in this study. To analyze the concentration levels of CHI3L1 protein, bronchial lavage fluids were examined.

Results

Forced expiratory volume in one second, %predicted (%FEV1), was significantly decreased in homozygotes of rs1214194 compared to heterozygotes and wild type. The age of onset of adult bronchial asthma was significantly younger in GG homozygotes of rs4950928 and AA homozygotes of rs1214194 than in the other two genotypes. The concentration of CHI3L1 protein in bronchial lavage fluid increased in both homozygotes of rs4950928 and rs1214194.

Conclusions

Our study demonstrated that the homozygotes of rs4950928 and rs1214194 of CHI3L1 might predict an early onset of bronchial asthma and have the propensity to promote airway remodeling.

Trial registration JMA-IIA00045 remodeling-ICS

Keywords

Bronchial asthma Single nucleotide polymorphisms Chitinase 3-like 1 

Abbreviations

CHI3L1

chitinase 3-like 1

SNPs

single nucleotide polymorphisms

BLF

bronchial lavage fluid

FVC

forced vital capacity

FEV1

forced expiratory flow volume in one second

NS

not significant

BALF

bronchoalveolar lavage fluid

BRP-39

breast regression protein-39

Background

Bronchial asthma is a disorder of the conducting airways that leads to variable airflow obstructions in association with airway hyperresponsiveness and a local accumulation of inflammatory cells, particularly Th2-type lymphocytes, eosinophils, and mast cells [1]. Allergens, such as those from mite and fungal exposure, up-regulate adaptive and innate immune responses, leading to the production of proinflammatory and profibrotic factors that may ultimately contribute to airway remodeling [2, 3]. Polysaccharide chitin, which is a polymer of N-acetylglucosamine, is found in the walls of fungi; exoskeleton of crabs, shrimp, and insects; the microfilarial sheath of parasitic nematodes; and the lining of the digestive tracts of many insects [4, 5, 6, 7, 8]. Chitinases are the enzymes that digest chitin polymer, and human subjects have 2 chitinases encoded in their genome: chitotriosidase and acidic mammalian chitinase (AMCase). AMCase and the chitinase-like protein YKL-40/chitinase 3-like 1 (CHI3L1), which lacks chitinase activity, were shown to play a critical role in inflammation driven by Th2-type cells and were expressed at high levels in tissues from patients with asthma [9, 10, 11]. YKL-40/CHI3L1 are produced by a variety of cells, including neutrophils, monocytes, macrophages, chondrocytes, synovial cells, endothelial cells, and tumor cells [12, 13]. Serum [10], lung, bronchial tissues [14], and sputum [15] have been noted in patients with bronchial asthma. Moreover, single nucleotide polymorphisms (SNPs) in CHI3L1 have been associated with a risk of bronchial asthma, bronchial asthma severity, and pulmonary function in populations of European ancestry [15]. Although it appears that YKL-40/CHI3L1 is strongly associated with both innate and adaptive immune responses [16], the correlation of these SNPs and the age of onset of bronchial asthma has not been demonstrated. In the current study, we aimed to assess whether variants in the CHI3L1 rs4950928 and rs1214194 genotypes were associated with lung function, the age of onset, and the airway expression of CHI3L1 protein in Japanese adult asthmatic patients.

Methods

Study subjects

All study subjects were recruited from the Iwate Medical University Hospital. Patients aged ≥ 18 years were eligible if they had a diagnosis of asthma as defined by the American Thoracic Society criteria for ≥ 5 years and were using inhaled corticosteroid (ICS) at a stable dose for ≥ 1 year before screening. Well-controlled asthmatic patients who had no other medical disorders, who had smoked less than 10-pack-years, and who had not been exposed to environmental hazards were considered for the study to exclude concomitant COPD. Well-controlled asthma symptoms were defined as meeting none of the following criteria in the previous 4 weeks [17]: (1) daytime asthma symptoms showing more than twice/week, (2) any night walking due to asthma, (3) a reliever needed for symptoms more than twice/week, and (4) any activity limitation due to asthma. This study was approved by the Iwate Medical University Hospital Ethics Committee (H20-119) and registered with Clinical Trials (JMA-IIA00045 remodeling-ICS). Prospective patients were notified of our desire to include them in our study and were asked if they would be willing to participate. Upon acceptance, the subjects provided written informed consent according to the ethical protocols of our institution. Subjects were assessed for age, height, body weight, sex, age of onset, eosinophil counts, serum IgE concentration, and spirometry. The data for age of onset of bronchial asthma were self-reported. Spirometry was performed (HI-801, CHEST, Tokyo, Japan) according to the ERS/ATS Guidelines [18]. Airway methacholine responsiveness was measured using an Astograph (Jupiter 21, CHEST, Tokyo, Japan) according to the method described by Takishima et al. [19]. The examination was performed by measuring dose–response curves of respiratory resistance during continuous inhalation of methacholine at a stepwise incremental concentration. Methacholine hydrochloride in isotonic saline was gradually increased to 49, 98, 195, 390, 781, 1563, 3125, 6250, 12,500, and 25,000 μg/mL [20]. DNA was isolated from lymphocytes using standard procedures. Subjects were genotyped for rs4950928 and rs1214194 using a 7500 Fast Real-Time PCR System (Life Technologies Japan, Tokyo, Japan).

Fiberoptic bronchoscopy and specimen handling

Asthmatic patients underwent fiberoptic bronchoscopic examinations during ICS treatment. Asthmatic bronchial lavage fluids (BLF) were obtained from (i) patients harboring CC (wild type) of rs4950928; (ii) patients harboring GG (homozygous) of rs4950928; (iii) patients harboring GG (wild type) of rs1214194; and (iv) patients harboring AA (homozygous) of rs1214194. Bronchial lavage was performed by inserting a flexible fiberoptic bronchoscope (Olympus; Olympus Optical Co Ltd, Tokyo, Japan) under local anesthesia, as previously described [21]. BLF was extracted from one of the subsegmental bronchi of the left lingular division by injection of 20 mL aliquots of sterile saline pre-warmed to 36.5 °C twice and gently aspirated back into polypropylene tubes kept on ice. We obtained 20–25 mL of BLF from each asthma patient. Immediately after lavage, mucus was removed from the fluid by filtration through gauze, total and differential cell counts were performed, and the fluid was then centrifuged at 200×g for 10 min at 4 °C. The supernatant was decanted and stored at − 80 °C. Ten milliliters of BLF supernatant was concentrated to 1.0 mL (tenfold) by centrifugation using Centrifugal Filter Devices (Amicon Ultra-0.5, Merck Millipore, Darmstadt, Germany). CHI3L1 levels were measured in duplicate in BLF specimens using a commercially available ELISA kit for Human Chitinase 3-like 1 Immunoassay (R&D Systems, Inc., Minneapolis, MN, USA). The mean value of the 2 duplicates was used in the statistical analyses. Duplicate samples with coefficients of variation greater than 20% were reassayed.

Statistical analysis

Statistical analyses were performed using JMP version 11 (SAS Institute Inc., Tokyo, Japan). All data were expressed as the mean ± standard error. Comparisons of the patients’ characteristics between the three groups were performed using one-way ANOVA. Post hoc multiple comparisons were performed using the Tukey–Kramer test for differences among all groups. Comparisons of the total and differential cell counts, and the concentration of CHI3L1 in BLF were performed using a t-test. P values < 0.05 were considered significant.

Results

Subject demographics and enrolment

Of 390 asthmatic patients screened, 381 of rs4950928 and 368 of rs1214194 were successfully genotyped (≥ 94%). We identified 270, 90, and 21 subjects that had CC wild type, CG heterozygotes, and GG homozygotes, respectively, for rs4950928 (Table 1). There were no significant differences in age at study enrolment, sex, eosinophil count status, serum IgE concentration, pulmonary function, or receiving dose of ICS. We also identified 170, 157, and 41 subjects that had GG wild type, GA heterozygotes, and AA homozygotes, respectively, for rs1214194 (Table 2). AA homozygotes had a significantly lower forced expiratory flow volume in one second, %predicted (%FEV1) compared to other genotypes (Table 2). There were significant differences in the age of bronchial asthma onset among the three groups for rs4950928 and rs1214194 (Tables 1, 2). We next restricted the study to adult-onset bronchial asthma (excluded child-onset asthma) and compared the age of onset. The age of onset of adult bronchial asthma was significantly lower in GG homozygotes of rs4950928 (Table 3) and AA homozygotes of rs1214194 than in the other two genotypes (Table 4).
Table 1

Patient characteristics according to the rs4950928 genotype

rs4950928 genotype

CC (n = 270)

CG (n = 90)

GG (n = 21)

P value

Age, years

57.6 ± 1.0

58.5 ± 1.7

55.8 ± 3.7

NS

Height, cm

158.4 ± 0.6

159.1 ± 1.0

160.4 ± 2.1

NS

Body weight, kg

59.4 ± 0.7

60.7 ± 1.2

60.8 ± 2.7

NS

Sex, n (%)

110 men (41)

41 men (46)

12 men (57)

NS

Age of onset, years

42.5 ± 1.3

44.3 ± 2.2

31.1 ± 4.5

0.032

Eosinophil count/μL

300.9 ± 17.4

359.5 ± 29.9

277.6 ± 65.1

NS

IgE level, IU/mL

412.1 ± 58.0

435.2 ± 77.9

565.4 ± 233.2

NS

GINA asthma severity, n (%)

 Mild

58 (21.5)

21 (23.3)

6 (28.6)

 Moderate

105 (38.9)

33 (36.7)

12 (57.1)

 Severe

107 (39.6)

36 (40.0)

3 (14.3)

Pulmonary function

 %FVC

103.3 ± 2.0

104.3 ± 3.4

103.51 ± 9.8

NS

 FEV1, L

2.3 ± 0.1

2.3 ± 0.1

2.3 ± 0.2

NS

 FEV1/FVC, %

72.9 ± 0.7

70.8 ± 1.2

70.2 ± 2.6

NS

 %FEV1

98.9 ± 1.5

98.8 ± 2.6

95.1 ± 5.3

NS

  Mild

105.8 ± 3.1

106.8 ± 5.4

91.0 ± 26.5

  Moderate

100.0 ± 2.3

100.5 ± 4.3

103.3 ± 22.6

  Severe

94.2 ± 2.3

92.5 ± 4.1

92.2 ± 33.1

 Equivalent FP CFC dose (μg/day)

382.1 ± 17.0

362.4 ± 29.3

228.0 ± 63.7

NS

Data are expressed as the mean ± standard error

GINA, Global Initiative for Asthma; FVC, forced vital capacity; FEV1, forced expiratory flow volume in one second; NS, not significant among the three groups; FP, fluticasone propionate; CFC, chlorofluorocarbon propellant

Table 2

Patient characteristics according to the rs1214194 genotype

rs1214194 genotype

GG (n = 170)

GA (n = 157)

AA (n = 41)

P value

Age, years

57.8 ± 1.2

57.7 ± 1.3

58.4 ± 2.7

NS

Height, cm

158.8 ± 0.7

159.0 ± 0.7

157.7 ± 1.5

NS

Body weight, kg

60.5 ± 1.9

59.6 ± 1.0

59.1 ± 1.9

NS

Sex, n (%)

71 men (42)

71 men (45)

15 men (37)

NS

Age of onset, years

43.5 ± 1.6

43.2 ± 1.7

34.2 ± 3.3

0.032

Eosinophil count/μL

315.6 ± 21.7

310.6 ± 23.4

331.7 ± 46.1

NS

IgE level, IU/mL

473.7 ± 97.5

504.4 ± 101.2

235.7 ± 199.2

NS

GINA asthma severity, n (%)

 Mild

35 (20.6)

34 (21.7)

4 (9.8)

 Moderate

70 (41.2)

61 (38.9)

18 (43.9)

 Severe

65 (38.2)

62 (39.5)

19 (46.3)

Pulmonary function

 %FVC

104.0 ± 2.6

104.0 ± 2.4

97.2 ± 5.9

NS

 FEV1, L

2.3 ± 0.1

2.3 ± 0.1

2.1 ± 0.2

NS

 FEV1/FVC, %

72.4 ± 0.9

72.2 ± 1.0

70.9 ± 1.8

NS

 %FEV1

99.6 ± 2.0

98.8 ± 1.8

87.9 ± 3.6

0.04

  Mild

106.7 ± 4.3

102.7 ± 3.8

91.0 ± 11.8

  Moderate

103.1 ± 3.0

99.3 ± 2.8

89.5 ± 5.6

  Severe

92.0 ± 3.1

95.1 ± 3.8

85.8 ± 5.4

 Equivalent FP CFC dose (μg/day)

325.6 ± 20.8

363.1 ± 22.3

432.1 ± 44.1

NS

Data are expressed as the mean ± standard error

GINA, Global Initiative for Asthma; FVC, forced vital capacity; FEV1, forced expiratory flow volume in one second; NS, not significant among the three groups; FP, fluticasone propionate; CFC, chlorofluorocarbon propellant

Table 3

Age of adult-onset asthma according to the rs4950928 genotype

rs4950928 genotype

CC (n = 233)

CG (n = 78)

GG (n = 18)

P value

Age of onset, years

47.6 ± 1.1

48.4 ± 1.9

35.7 ± 4.0

0.013

Data are expressed as the mean ± standard error

Table 4

Age of adult-onset asthma according to the rs1214194 genotype

rs1214194 genotype

GG (n = 148)

GA (n = 135)

AA (n = 34)

P value

Age of onset, years

48.2 ± 1.4

48.6 ± 1.5

38.9 ± 2.9

0.009

Data are expressed as the mean ± standard error

Detection of clinically relevant CHI3L1 levels in BLF supernatants

We performed a bronchoscopy and collected BLF from the two groups to confirm whether GG and AA homozygotes of rs4950928 and rs1214194, respectively, expressed any increased CHI3L1 protein levels. Four patients who were genotyped as CC and 5 patients as GG of rs4950928 harboring wild type of rs1214194 and 6 patients who were genotyped as GG and 4 patients as AA of rs1214194 harboring wild type of rs4950928 were accepted for the BLF studies, which was performed following recommended safety procedures and was well tolerated in all subjects. There were no significant differences in total and differential cell counts between wild type and homozygous. In contrast, CHI3L1 levels in BLF were significantly increased in patients who were homozygous compared to wild type (Table 5).
Table 5

Cell differentials and CHI3L1 levels in bronchial lavage fluid

 

rs4950928

rs1214194

CC (n = 4)

GG (n = 5)

GG (n = 6)

AA (n = 4)

Total cell/mL (×104)

11.5 ± 2.7

10.2 ± 2.4

12.0 ± 2.3

13.3 ± 2.9

 Eosinophils, %

1.5 ± 0.5

1.9 ± 0.5

4.0 ± 1.5

6.5 ± 1.9

 Macrophages, %

81.3 ± 4.7

75.0 ± 4.2

78.3 ± 4.0

72.5 ± 4.9

 Lymphocytes, %

12.5 ± 3.1

15.0 ± 2.8

13.8 ± 3.1

15.0 ± 3.8

 Neutrophils, %

2.3 ± 0.9

4.6 ± 0.8

3.3 ± 1.1

5.3 ± 1.4

CHI3L1, pg/mL

140.3 ± 313.5

1144.8 ± 280.4*

179.3 ± 155.30

770.8 ± 190.2

Data are expressed as the mean ± standard error

P < 0.05 compared with CC, P < 0.05 compared with GG

Discussion

In this study, we investigated genetic variants of CHI3L1 related to clinical characteristics in Japanese asthmatic patients. Several new findings have emerged from this study. First, we demonstrated that asthmatic patients with genetic variants of rs1214194 had a reduced %FEV1. Second, the age of onset of bronchial asthma was significantly younger in homozygotes of rs4950928 and rs1214194 than in other genotypes. When compared with restricted adult-onset asthma, the age of onset was significantly younger in homozygotes than in the wild type and heterozygotes genotypes. Third, CHI3L1 in BLF from CHI3L1 homozygotes of GG of rs4950928 and AA of rs1214194 increased compared to the wild type in asthmatic patients. Previous population studies of genetic variation in the CHI3L1 gene and bronchial asthma have shown an association with the promoter SNP rs4950928, intronic SNP rs1214194, and a decreased %FEV1 [15]. However, our studies demonstrated that %FEV1 was decreased in asthmatic patients harboring only homozygotes of rs1214194. One explanation for these differences may depend on medical treatment. Our prospective studies have indicated that STAT4 TT of rs925847 and IL13 AA of rs20541 are potential genomic biomarkers that predict lower pulmonary function. High-dose inhaled corticosteroid treatment increased the pulmonary function of patients homozygous for IL13AA of rs20541 but not of patients homozygous for STAT4 TT of rs925847 [22]. Another analysis revealed an association between the homozygous GLCCI1 rs37972 and rs37973 and the asthmatic treatment steps used with the Japanese population, showing an OR of 2.78 and 2.28, respectively, but not with pulmonary function [23]. We concluded that the recent wide use of anti-IgE and tiotropium produced a clinically meaningful reduction in the exacerbation rate and a sequential improvement in pulmonary function. Thus, decreased FEV1 was dependent on the genetic background and treatment content.

YKL-40/CHI3L1 plays a role in the pathophysiology of bronchial asthma by modulating innate and adaptive immune responses. Surprisingly, to date, the effects of genetic variation in CHI3L1 on the age of onset of bronchial asthma have not been addressed. To clarify this issue, we compared the ages of adult-onset bronchial asthma between the genotypes for SNPs in CHI3L1 in Japanese patients. It is generally considered that early-onset asthma included child-onset asthma and adult-onset asthma. However, based on the remaining possibility of the prevention of bronchial asthma development via an improvement of lifestyle habit, it should be distinguished from the perspective of preventive medicine. Genotyping of CHI3L1 could be considered significant if the development of bronchial asthma can be avoided in men who are found to have a genetic variation of CHI3L1, have a family history of bronchial asthma, and are notified early enough to be able to sufficiently adjust their lifestyle habits. Studies of this have added to our understanding of the importance of genetic variations by demonstrating that CHI3L1 rs4950928 and rs1214194 genotypes play a critical role in early-onset adult asthma. Bronchial asthma should be suspected in anyone with episodic wheezing, shortness of breath, and cough, especially if more than one of the symptoms is worse at night or is precipitated by an upper airway infection; however, these symptoms are relatively nonspecific in adult individuals. Using an examination of SNPs in CHIL3L1 might promote early detection and intervention in preventing airflow obstructions.

Increased levels of the YKL-40 protein have been found in patients with a broad spectrum of pathologies, including those with rheumatoid arthritis [13], obstructive sleep apnea syndrome [24], solid malignancies [25], atherosclerosis [26], and diabetes mellitus [27, 28]. Previous asthmatic models have demonstrated that diminished antigen-induced responses in chitinase knockout mice were associated with increased eosinophil apoptosis [12]. The potential importance of YKL-40 can also be seen in rheumatoid arthritis, in which elevated serum YKL-40 levels were correlated with the severity of joint involvement [29]. As a result, these observations indicated that YKL-40 might reflect a local inflammation. To our limited knowledge, no other reports have analyzed YKL-40 in BLF, but only in serum [10], sputum [15], and bronchoalveolar lavage fluid (BALF) [30]. With respect to asthma pathophysiology, only BLF reflects chronic airway allergic inflammation and the exact concentration of chemical mediators; therefore, it is still too early to regard the concentration of YKL-40 in the sputum and BALF as a marker of whole bronchial inflammation in bronchial asthma. The aim of the present study was to determine the concentration of YKL-40 in BLF. Further investigations to compare the concentrations in serum, sputum and BLF are needed. The expression of the chitinase breast regression protein (BRP)-39, which is the murine equivalent of YKL-40, was induced by cigarette smoke exposure in a mouse model [31]. The induction by cigarette smoke is IL-1 receptor (R) 1 dependent, which is unique from BRP-39 induction in house dust mite-induced allergic inflammation, which is both IL-1R1 and IL-13 independent. In a human specimen study, YKL-40 promoted bronchial smooth muscle cell proliferation and migration. The cells expressing YKL-40 and BRP-39 in the airways were identified as bronchial epithelial cells and macrophages. Bronchial epithelial expression of YKL-40 is positively correlated with bronchial smooth muscle mass in patients with bronchial asthma [14]. This suggests that cigarette smoke-induced YKL-40 in a Th2 milieu progresses airway remodeling in asthmatic patients. We cannot deny the possibility of advancement in the airway remodeling of bronchial asthmatic patients harboring genetic variants of rs4950928 or rs1214194 and who had an increased YKL-40 in the bronchus due to cigarette smoke. Further examinations are needed to verify the relationships between genetic background, smoking, and declined pulmonary function data.

Conclusions

In conclusion, this study demonstrated that rs4950928 and rs1214194 homozygotes of CHI3L1 might be promising genomic biomarkers as predictors of progressing airway remodeling. Before the age of onset of bronchial asthma for patients who have these genetic variants, we need to consider the development of a preventative program that can be implemented before symptoms occur or worse.

Notes

Authors’ contributions

KA and YN conceived the idea and designed, were responsible for this cohort from the beginning and participated in the planning and collection of the data. KY and MM performed the data analysis. All authors have written the manuscript together. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to acknowledge M. Niisato, T. Yamaguchi, and S. Oura (Iwate Medical University School of Medicine) for their help in performing this study. All authors thank Drs. Qutayba Hamid and James G. Martin (McGill University) for their helpful comments.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Data available from corresponding author.

Ethics approval and consent to participate

This study was approved by the Iwate Medical University Hospital Ethics Committee (H20-119) and registered with Clinical Trials (JMA-IIA00045 remodeling-ICS). Prospective patients were notified of our desire to include them in our study and were asked if they would be willing to participate. Upon acceptance, the subjects provided written informed consent according to the ethical protocols of our institution.

Funding

None.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992;326:298–304.CrossRefPubMedGoogle Scholar
  2. 2.
    Kim HY, DeKruyff RH, Umetsu DT. The many paths to asthma: phenotype shaped by innate and adaptive immunity. Nat Immunol. 2010;11:577–84.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, et al. A critical role for eosinophils in allergic airways remodeling. Science. 2004;305:1776–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Araujo AC, Souto-Padron T, de Souza W. Cytochemical localization of carbohydrate residues in microfilariae of Wuchereria bancrofti and Brugia malayi. J Histochem Cytochem. 1993;41:571–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol. 1994;48:471–97.CrossRefPubMedGoogle Scholar
  6. 6.
    Fuhrman JA, Piessens WF. Chitin synthesis and sheath morphogenesis in Brugia malayi microlariae. Mol Biochem Parasitol. 1985;17:93–104.CrossRefPubMedGoogle Scholar
  7. 7.
    Neville AC, Parry DA, Woodhead-Galloway J. The chitin crystallite in arthropod cuticle. J Cell Sci. 1976;21:73–82.PubMedGoogle Scholar
  8. 8.
    Shahabuddin M, Kaslow DC. Plasmodium: parasite chitinase and its role in malaria transmission. Exp Parasitol. 1994;79:85–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, Cohn L, et al. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science. 2004;304:1678–82.CrossRefPubMedGoogle Scholar
  10. 10.
    Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med. 2007;357:2016–27.CrossRefPubMedGoogle Scholar
  11. 11.
    Lee CG, Dela Cruz CS, Ma B, Ahangari F, Zhou Y, Halaban R, et al. Chitinase-like proteins in lung injury, repair, and metastasis. Proc Am Thorac Soc. 2012;9:57–61.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, Da Silva CA, et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med. 2009;206:1149–66.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268:25803–10.PubMedGoogle Scholar
  14. 14.
    Bara I, Ozier A, Girodet PO, Carvalho G, Cattiaux J, Begueret H, et al. Role of YKL-40 in bronchial smooth muscle remodeling in asthma. Am J Respir Crit Care Med. 2012;185:715–22.CrossRefPubMedGoogle Scholar
  15. 15.
    Gomez JL, Crisafi GM, Holm CT, Meyers DA, Hawkins GA, Bleecker ER, et al. Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40. J Allergy Clin Immunol. 2015;136:51–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Reese TA, Liang HE, Tager AM, Luster AD, Van Rooijen N, Voehringer D, et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature. 2007;447:92–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention 2015. http://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf. Accessed 1 Oct 2017.
  18. 18.
    Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.CrossRefPubMedGoogle Scholar
  19. 19.
    Takishima T, Hida W, Sasaki H, Suzuki S, Sasaki T. Direct-writing recorder of the dose-response curves of the airway to methacholine. Clinical application. Chest. 1981;80:600–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Hoshino M, Nakamura Y. Anti-inflammatory effects of inhaled beclomethasone dipropionate in nonatopic asthmatics. Eur Respir J. 1996;9:696–702.CrossRefPubMedGoogle Scholar
  21. 21.
    Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax. 1998;53:835–41.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Nakamura Y, Suzuki R, Mizuno T, Abe K, Chiba S, Horii Y, et al. Therapeutic implication of genetic variants of IL13 and STAT4 in airway remodelling with bronchial asthma. Clin Exp Allergy. 2016;46:1152–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Chiba S, Nakamura Y, Mizuno T, Abe K, Horii Y, Nagashima H, et al. Impact of the genetic variants of GLCCI1 on clinical features of asthmatic patients. Clin Respir J. 2017.  https://doi.org/10.1111/crj.12647.Google Scholar
  24. 24.
    Mutlu LC, Tülübaş F, Alp R, Kaplan G, Yildiz ZD, Gürel A. Serum YKL-40 level is correlated with apnea hypopnea index in patients with obstructive sleep apnea syndrome. Eur Rev Med Pharmacol Sci. 2017;21:4161–6.PubMedGoogle Scholar
  25. 25.
    Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194–202.CrossRefPubMedGoogle Scholar
  26. 26.
    Fach EM, Garulacan LA, Gao J, Xiao Q, Storm SM, Dubaquie YP, et al. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics. 2004;3:1200–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H. YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care. 2009;32:323–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Nielsen AR, Erikstrup C, Johansen JS, Fischer CP, Plomgaard P, Krogh-Madsen R, et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes. 2008;57:3078–82.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis. 2001;60:619–26.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Gavala ML, Kelly EA, Esnault S, Kukreja S, Evans MD, Bertics PJ, et al. Segmental allergen challenge enhances chitinase activity and levels of CCL18 in mild atopic asthma. Clin Exp Allergy. 2013;43:187–97.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Nikota JK, Botelho FM, Bauer CM, Jordana M, Coyle AJ, Humbles AA, et al. Differential expression and function of breast regression protein 39 (BRP-39) in murine models of subacute cigarette smoke exposure and allergic airway inflammation. Respir Res. 2011;12:39.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Kazuyuki Abe
    • 1
  • Yutaka Nakamura
    • 2
  • Kohei Yamauchi
    • 1
  • Makoto Maemondo
    • 1
  1. 1.Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal MedicineIwate Medical University School of MedicineMoriokaJapan
  2. 2.Department of Allergy and RheumatologyNippon Medical School Graduate School of MedicineTokyoJapan

Personalised recommendations